Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bradley Miller

Pediatric Endocrinology Minneapolis, MN Medical Doctor

NPI 1184633059 CMS profile 234387

420 Delaware St Se, Mmc 404 University Of Minnesota, Minneapolis, MN 55455

Open in the dashboard

General payments

$465,219

357 records reported · program years 2019–2025

Research payments

$23,790

Paid to them · 13 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$861,431 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Bradley Miller of Minneapolis, MN is reported in the CMS Open Payments database as having received $465,219 across 357 general payments and $23,790 in research payments paid to them. Separately, studies naming them as principal investigator received $861,431 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $79,001 55
2025 Research $6,730 3
2024 General $51,079 44
2023 General $155,254 113
2023 Research $3,980 2
2022 General $52,945 32
2022 Research $4,470 3
2021 General $33,100 21
2021 Research $8,610 5
2020 General $31,292 26
2019 General $62,547 66

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bradley Miller
  • Pediatric Endocrinology median
  • Middle half of Pediatric Endocrinology
  • National median

In program year 2025, general payments to Bradley Miller were reported at $79,001. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.

Show as a table
Year Bradley Miller Pediatric Endocrinology median Middle half National median
2019 $62,547 $196 $68–$845 $163
2020 $31,292 $124 $37–$722 $114
2021 $33,100 $134 $35–$691 $132
2022 $52,945 $177 $47–$726 $149
2023 $155,254 $236 $75–$887 $160
2024 $51,079 $259 $91–$979 $164
2025 $79,001 $293 $106–$1,640 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Health Care AG $122,429 64 payments
  2. BioMarin Pharmaceutical Inc. $60,768 86 payments
  3. Novo Nordisk AS $40,993 20 payments
  4. Novo Nordisk Inc $39,689 44 payments
  5. Pfizer Inc. $39,578 22 payments
  6. Tolmar, Inc. $31,245 14 payments
  7. Ascendis Pharma, Inc. $27,086 23 payments
  8. Hexal AG $20,237 15 payments
  9. TOLMAR Pharmaceuticals, Inc. $17,913 14 payments
  10. Soleno Therapeutics, Inc. $14,802 11 payments
  11. Other $50,478 44 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $229,143 90 payments
  2. Travel and Lodging $110,315 106 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $84,943 35 payments
  4. Honoraria $27,843 10 payments
  5. Food and Beverage $10,679 108 payments
  6. Education $2,296 8 payments
Products named General payments · program years 2019–2025
  1. Norditropin Growth Hormone $61,840 40 payments
  2. Sogroya $49,715 20 payments
  3. FENSOLVI $44,468 18 payments
  4. Norditropin Growth Hormone $26,023 25 payments
  5. OMNITROPE $21,749 19 payments
  6. GENOTROPIN $20,046 7 payments
  7. NGENLA $15,554 8 payments
  8. SKYTROFA $13,716 12 payments
  9. VOXZOGO 1.2mg $11,613 27 payments
  10. VYKAT XR $10,855 10 payments
  11. Other $58,110 63 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Pfizer Inc. $23,790 13 payments

Records

370 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Endocrinology in Minnesota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record